research Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
Search
for
Sort by
Research
930-960 / 1000+ resultsresearch LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research Blocking Potassium Channels (Kv1.3): A New Treatment Option for Alopecia Areata?
Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.
research Azathioprine hypersensitivity in bullous pemphigoid
A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.
research The Antiandrogens
research Identification of drug-specific public TCR driving severe cutaneous adverse reactions
Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
research Successful Management of Netherton Syndrome Using IVIG and Dupilumab: A Case Report
IVIG and dupilumab effectively improved symptoms in a child with Netherton syndrome.
research Mimosine Dipeptide Enantiomsers: Improved Inhibitors against Melanogenesis and Cyclooxygenase
Mimosine dipeptides are promising for treating hyperpigmentation and inflammation.
research Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata
Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.
research 039 Expansion of regulatory T Cells restrains pathogenic CD8 T Cells in a murine model of alopecia areata
Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.
research Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.
research Unmasking Melasma: Confronting the Treatment Challenges
Melasma treatment is difficult, but combination therapies and personalized plans show promise.
research Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia
M50054 may help treat hepatitis and hair loss from chemotherapy.
research THERAPEUTIC CHALLENGES IN POLYAUTOIMMUNITY: ANIFROLUMAB FOR LUPUS ERYTHEMATODES IN OVERLAPPING AUTOIMMUNE SYNDROMES
Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
research Locally Synthetized 17-β-Estradiol Reverses Amyloid-β-42-Induced Hippocampal Long-Term Potentiation Deficits
A brain-made hormone can protect against memory-related brain damage caused by harmful proteins.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research Treatment Effects of Intradermal Botulinum Toxin Type A Injection on Alopecia Areata
Botulinum toxin type A injections are not effective for severe alopecia areata.
research New Nonsteroidal Molecules as Blockers of the Steroidogenic Pathway
New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
research Topical immunotherapy in alopecia areata
Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.
research N‑K GM SERIES: THE COMPLETE GEOMETRIC MEDICINE LIBRARY — From Discovery to Deployment: SELECTIVE‑ANTI‑BACTERIAL‑GM2, SELECTIVE‑ANTI‑PATHOGENIC‑FUNGI‑GM2, and the CMC Pocket Delivery System A Comprehensive Framework for Precision Antimicrobials — 1,000,000,000:1 Selectivity, Zero Ecological Harm, Free for Humanity
The N-K GM Series offers highly selective, eco-friendly antimicrobials free for everyone.
research New Aromatic Esters of Progesterone as Antiandrogens
New progesterone-based compounds can block male hormones.
research Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses
Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.
research Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
research De novo designed bifunctional proteins for targeted protein degradation
Newly designed proteins can effectively degrade specific proteins in cells, offering a promising alternative for targeted protein degradation.
research De novo designed bifunctional proteins for targeted protein degradation
Newly designed proteins can effectively degrade specific proteins in cells, offering a potential new therapy method.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research The role of natural killer cells in autoimmune blistering diseases
Natural killer cells play a key role in autoimmune skin diseases like pemphigus vulgaris.
research 026 Targeting pathogenic MICA-NKG2D interactions by statins: A novel adjunct treatment strategy for alopecia areata management?
Statins may help treat alopecia areata by reducing harmful immune interactions.
research A randomized controlled clinical trial of recombinant interferon α‐2b in the treatment of acute post‐transfusion hepatitis C: A preliminary report
Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.